Once Broken – May Break Again

Angie Szumlinski Health, Studies

According to a recent study published in the Lancet, there is a crisis in the under-treatment of osteoporosis with a decline in the prescribing of oral and intravenous bisphosphonates in the United States. The rates of initiation of osteoporosis medication within 6 months of hospitalization for hip fracture have declined over the past 15 years from 10 to 3%. In …

Osteoporosis Key Findings

Angie Szumlinski Health, Studies

Osteoporosis is the most common bone disease and is characterized by weakening of bone tissue, bone structure, and strength, and may lead to increased risk of fractures. Low bone mass increases the risk of developing osteoporosis. In the United States in 2010, an estimated 10.2 million people aged 50 and over had osteoporosis and about 43.3 million more people had …

Psoriatic Arthritis and Osteoporosis

Angie Szumlinski News

A recent study published in Arthritis Care and Research, investigators found a similar prevalence of osteoporosis and osteopenia in patients with psoriatic arthritis compared to the general population. Patients with psoriatic arthritis who are more likely to undergo osteoporosis screening are those with traditional risk factors including age and menopause, as well as those with features suggestive of higher disease …

Osteoporosis Treatment Beyond 5 Years

Angie Szumlinski Health, Studies

For more than 2 decades, bisphosphonate drugs have been a first-line therapy for preventing osteoporotic fractures, based on strong clinical evidence showing significant fracture risk reduction within the first 3 to 5 years of treatment. However, data regarding the optimal duration of bisphosphonate treatment to minimize fracture risk beyond this initial period of time are limited. In September 2015, a …

Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention

Angie Szumlinski Health, News

A recent study to summarize the effects of long-term osteoporosis drug treatment and of osteoporosis drug treatment discontinuation and holidays found that long-term alendronate, zoledronate, and oral hormone therapy reduced nonvertebral fractures in older women, with oral hormone therapy also reducing hip fractures. While absolute reductions in typical fractures with long-term bisphosphonates are large relative to increases in AFF, reduced …